AbbVie is a U.S. biopharmaceutical company focused on discovering and delivering innovative medicines and solutions. It develops therapies across major disease areas and serves patients globally.
Trump secured agreements with 16 pharmaceutical companies tied to TrumpRx.gov, including most-favoured-nation pricing and direct-to-patient discounts. Several companies disclosed price cuts for obesity, diabetes, insulin and other medicines.
The global schizophrenia drugs market is projected to grow from USD 9.1 billion in 2026 to USD 15.8 billion by 2036 at a 5.8% CAGR. Long-acting injectables and second-generation antipsychotics lead the market.
AbbVie raised 2026 revenue and EPS guidance after first-quarter results beat estimates, with Skyrizi and Rinvoq driving growth. Humira erosion continued as neuroscience, oncology and pipeline assets supported the outlook.
European biotechs are exploring new immunotherapy targets beyond PD-1/PD-L1, including BTLA, TIGIT, and SLAMF6. Lund University researchers discovered a SLAMF6-mediated immune evasion mechanism. BioNTech and GenMab are advancing next-generation ICIs and bispecific antibodies through strategic partnerships.
Compass Therapeutics reported mixed Phase 2/3 data for tovecimig in biliary tract cancer and plans to meet with the FDA for a BLA discussion. The study met its primary ORR endpoint (17% vs 5%), while PFS and OS data are due late this quarter.
AbbVie filed an sBLA for SKYRIZI as a subcutaneous induction therapy for Crohn's disease, supported by Phase 3 AFFIRM data. SKYRIZI and Rinvoq combined for $25.9B in 2025 revenue, exceeding 2027 guidance. The FDA also approved Venclexta plus acalabrutinib in CLL.
AbbVie plans to build a $1.4 billion, 185-acre pharmaceutical campus in Durham, North Carolina. The site is expected to open by the end of 2028 and hire 734 employees while adding SVP manufacturing capacity.
Eli Lilly, AbbVie, Vertex, Gilead Sciences and Pfizer were identified as pharmaceutical stocks to watch, with Abbott Laboratories and McKesson appearing on a separate seven-stock list.
Biopharma companies face a $275b patent cliff as licensing activity shifts toward China. China represented almost half of 2025 licensing activity and contributes about 30% of the global biotech pipeline.
AbbVie said Skyrizi and Rinvoq generated $26.0 billion in 2025 sales and are expected to exceed $31 billion in 2026. The company said the two immunology drugs continue to offset Humira erosion and drive top-line growth.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07604558 |
A Study to Assess the Adverse Events and How Bretisilocin Intramuscular Injection Moves Through the Body of Healthy Adult Participants |
NOT_YET_RECRUITING | PHASE1 |
| NCT07604545 |
A Study to Assess the Use of Artificial Intellignce to Predict Eye Treatment Changes in Adult Participants With Diabetic Macular Edema |
NOT_YET_RECRUITING | |
| NCT07600762 |
A Study to Assess Adverse Events, Tolerability and How a Single Oral Dose of Nascertib Moves Through the Body In Healthy Adult Japanese Participants |
RECRUITING | PHASE1 |
| NCT07600151 |
Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07599761 |
A Phase 1 Study to Assess the Effect of Itraconazole on ABBV-722 in Healthy Adult Participants |
RECRUITING | PHASE1 |
| NCT07599670 |
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenous ABBV-1758 Moves Through the Body of Adult Participants With Alzheimer's Disease |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07592273 |
Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema |
RECRUITING | PHASE2/PHASE3 |
| NCT07588568 |
A Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis |
NOT_YET_RECRUITING | PHASE2 |
| NCT07587008 |
Study to Assess Adverse Events and How Oral Emraclidine Moves Through the Body of Adult Healthy Volunteers |
NOT_YET_RECRUITING | PHASE1 |
| NCT07581002 |
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) |
NOT_YET_RECRUITING | PHASE2/PHASE3 |
